Antimicrobial resistance in Pseudomonas aeruginosa;Rezistencija na antibiotike u bakterije Pseudomonas aeruginosa

Infektoloski Glasnik

Volumn 32, Issue 2, 2012, Pages 71-80

  Gužvinec, Marija ^a   Butić, Iva ^a   Jelić, Marko ^a   Bukovski, Suzana ^a   Lucić, Sandra ^a   Andrašević, Arjana Tambić ^a  

^a Croatia   (Croatia)

Author keywords

lactamases; Clonal spread; Pseudomonas aeruginosa; Resistance

Indexed keywords

BETA LACTAMASE AMPC;

ANTIBIOTIC RESISTANCE; CELL MEMBRANE PERMEABILITY; CONFERENCE PAPER; GENE EXPRESSION; HUMAN; PSEUDOMONAS INFECTION;

EID: 84873675964     PISSN: 13312820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (75)

1. Paterson DL, Kim B-N. Pseudomonas aeruginosa. U: Mayers DL, Lerner SA, Ouellette M, Sobel JD, ur. Antimicrobial drug resistance. New York: Humana Press; 2009: 811-7.
2. Pier GB, Ramphal R. Pseudomonas aeruginosa. U: Mandell G, Bennett J, Dolin R, ur. Principles and practice of infectious diseases. Philadelphia: Elsevier Churchill Livingstone; 2005: 2587-615.
3. Blondel-Hill E, Henry DA, Speert DP. Pseudomonas. U: Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA, ur. Manual of clinical microbiology. Washington DC: American Society for Microbiology; 2007:734-48.
4. Govan JR, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 1996; 60: 539-74.
5. Spencer RC. Predominant pathogens found in the European Prevalence of Infection in Intensive Care Study. Eur J Clin Microbiol Infect Dis 1996; 15:281-5.
6. Edgeworth JD, Treacher DF, Eykyn SJ. A 25-year study of nosocomial bacteremia in an adult intensive care unit. Crit Care Med 1999;27:1421-8.
7. Navon-Venezia S, Ben-Ami R, Carmeli Y. Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting. Curr Opin Infect Dis 2005; 18:306-13.
8. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 2006; 50:43-8.
9. Kang CI, Kim SH, Park WB, i sur. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa. Microb Drug Resist 2005; 11:68-74.
10. Bergogne-Berezin E. Current guidelines for the treatment and prevention of nosocomial infections. Drugs 1999; 58:51-67.
11. Kang CI, Kim SH, Kim HB, i sur. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 2003; 37:745-51.
12. Klibanov OM, Raasch RH, Rublein JC. Single versus combined antibiotic therapy for gram-negative infections. Ann Pharmacother 2004; 38:332-7.
13. Linden PK, Kusne S, Coley K, Fontes P, Kramer DJ, Paterson D. Use of parenteral Colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 2003;37:e154-e160.
14. Balaji V, Jeremiah SS, Baliga PR. Polymyxins: Antimicrobial susceptibility concerns and therapeutic options. Indian J Med Microbiol 2011; 29:230-42.
15. Hancock RE, Brinkman FS. Function of Pseudomonas porins in uptake and efflux. Annu Rev Microbiol 2002; 56: 17-38.
16. Nikaido H. Outer membrane barrier as a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989; 33: 1831-6.
17. Trias J, Nikaido H. Outer membrane protein D2 catalyzes facilitated diffusion of carbapenems and penems through the outer membrane of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1990;34:52-7.
18. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002; 34:634-40.
19. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 2009; 22:582-610.
20. Li H, Luo YF, Williams BJ, Blackwell TS, Xie CM. Structure and function of OprD protein in Pseudomonas aeruginosa: from an - tibiotic resistance to novel therapies. Int J Med Microbiol 2012; 302:63-8.
21. Quale J, Bratu S, Gupta J, Landman D. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2006; 50: 1633-41.
22. Tsuji M, Ishii Y, Ohno A, Miyazaki S, Yamaguchi K. In vitro and in vivo antibacterial activities of S-4661, a new carbapenem. Antimicrob Agents Chemother 1998; 42:94-9.
23. Piddock LJ. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev 2006; 19: 382-402.
24. Poole K, Srikumar R. Multidrug efflux in Pseudomonas aeruginosa: components, mechanisms and clinical significance. Curr Top Med Chem 2001; 1:59-71.
25. Schweizer HP. Efflux as a mechanism of resistance to antimicrobials in Pseudomonas aeruginosa and related bacteria: unanswered questions. Genet Mol Res 2003; 2:48-62.
26. Ziha-Zarifi I, Lianes C, Kohler T, Pechere JC, Plesiat P. In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexA-MexB-OprM. Antimicrob Agents Chemother 1999; 43:287-91.
27. Poole K, Gotoh N, Tsujimoto H, i sur. Overexpression of the mexC-mexD-oprJ efflux operon in nfxB-type multidrug-resistant strains of Pseudomonas aeruginosa. Mol Microbiol 1996; 21: 713-24.
28. Morita Y, Komori Y, Mima T, Kuroda T, Mizushima T, Tsuchiya T. Construction of a series of mutants lacking all of the four major mex operons for multidrug efflux pumps or possessing each one of the operons from Pseudomonas aeruginosa PAO1: MexCD-OprJ is an inducible pump. FEMS Microbiol Lett 2001; 202: 139-43.
29. Morita Y, Kimura N, Mima T, Mizushima T, Tsuchiya T. Roles of MexXY- and MexAB-multidrug efflux pumps in intrinsic multidrug resistance of Pseudomonas aeruginosa PAOI. J Gen Appl Microbiol 2001; 47:27-32.
30. Jalal S, Wretlind B. Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa. Microb Drug Resist 1998; 4: 257-61.
31. Doi Y, Arakawa Y. 16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides. Clin Infect Dis 2007;45:88-94.
32. Zhao WH, Hu ZQ. Beta-lactamases identified in clinical isolates of Pseudomonas aeruginosa. Crit Rev Microbiol 2010; 36:245-58.
33. Poole K. Pseudomonas aeruginosa: resistance to the max. Front Microbiol 2011; 2:65.
34. Walther-Rasmussen J, Hoiby N. Class A carbapenemases. J Antimicrob Chemother 2007; 60:470-82.
35. Weidhagen GF, Poirel L, Nordmann P. Ambler class A extended-spectrum beta-lactamases in Pseudomonas aeruginosa: novel developments and clinical impact. Antimicrob Agents Chemother 2003; 47:2385-92.
36. Nordmann P, Guibert M. Extended-spectrum beta-lactamases in Pseudomonas aeruginosa. J Antimicrob Chemother 1998; 42: 128-31.
37. Empel J, Filczak K, Mrowka A, Hryniewicz W, Livermore DM, Gniadkowski M. Outbreak of Pseudomonas aeruginosa infections with PER-1 extended-spectrum beta-lactamase in Warsaw, Poland: further evidence for an international clonal complex. J Clin Microbiol 2007; 45:2829-34.
38. Tian GB, Adams-Haduch JM, Bogdanovich T, Wang HN, Doi Y. PME-1, an extended-spectrum beta-lactamase identified in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2011; 55:2710-3.
39. Villegas MV, Lolans K, Correa A, Kattan JN, Lopez JA, Quinn JP. First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase. Antimicrob Agents Chemother 2007; 51: 1553-5.
40. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-beta-lac-tamases: the quiet before the storm? Clin Microbiol Rev 2005; 18: 306-25.
41. Samuelsen O, Toleman MA, Sundsfjord A, i sur. Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion. Antimicrob Agents Chemother 2010; 54:346-52.
42. Zavascki AP, Barth AL, Goldani LZ. Nosocomial bloodstream infections due to metallo-beta-lactamase-producing Pseudomonas aeruginosa. J Antimicrob Chemother 2008; 61:1183-5.
43. Bosnjak Z, Bedenic B, Mazzariol A, Jarza-Davila N, Suto S, Kalenic S. VIM-2 beta-lactamase in Pseudomonas aeruginosa isolates from Zagreb, Croatia. Scand J Infect Dis 2010; 42:193-7.
44. Sardelic S, Pallecchi L, Punda-Polic V, Rossolini GM. Carbape-nem-resistant Pseudomonas aeruginosa carrying VIM-2 metallo-beta- lactamase determinants, Croatia. Emerg Infect Dis 2003; 9: 1022-3.
45. Sardelic S, Bedenic B, Colinon-Dupuich C, i sur. Infrequent finding of metallo-beta-lactamase VIM-2 in carbapenem-resistant Pseudomonas aeruginosa strains from Croatia. Antimicrob Agents Chemother 2012; 56:2746-9.
46. Jovcic B, Lepsanovic Z, Suljagic V, i sur. Emergence of NDM-1 metallo-beta-lactamase in Pseudomonas aeruginosa clinical isolates from Serbia. Antimicrob Agents Chemother 2011; 55: 3929-31.
47. Sanders CC, Sanders WE, Jr. Type I beta-lactamases of gram-negative bacteria: interactions with beta-lactam antibiotics. J Infect Dis 1986; 154:792-800.
48. Livermore DM, Brown DF. Detection of beta-lactamase-mediated resistance. J Antimicrob Chemother 2001; 48 Suppl 1:59-64.
49. Juan C, Gutierrez O, Oliver A, Ayestaran JI, Borrell N, Perez JL. Contribution of clonal dissemination and selection of mutants during therapy to Pseudomonas aeruginosa antimicrobial resistance in an intensive care unit setting. Clin Microbiol Infect 2005; 11: 887-92.
50. Rodriguez-Martinez JM, Poirel L, Nordmann P. Extended-spectrum cephalosporinases in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009; 53: 1766-71.
51. Poirel L, Naas T, Nordmann P. Diversity, epidemiology, and genetics of class D beta-lactamases. Antimicrob Agents Chemother 2010;54:24-38.
52. Sevillano E, Gallego L, Garcia-Lobo JM. First detection of the OXA-40 carbapenemase in P. aeruginosa isolates, located on a plasmid also found in A. baumannii. Pathol Biol (Paris) 2009; 57: 493-5.
53. El Garch F, Bogaerts P, Bebrone C, Galleni M, Glupczynski Y. OXA-198, an acquired carbapenem-hydrolyzing class D beta-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother 2011; 55:4828-33.
54. Ramirez MS, Tolmasky ME. Aminoglycoside modifying enzymes. Drug Resist Updat 2010; 13:151-71.
55. Magiorakos AP, Srinivasan A, Carey RB, i sur. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18:268-81.
56. Cholley P, Thouverez M, Hocquet D, Mee-Marquet N, Talon D, Bertrand X. Most multidrug-resistant Pseudomonas aeruginosa isolates from hospitals in eastern France belong to a few clonal types. J Clin Microbiol 2011; 49:2578-83.
57. Goossens H. Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group. Clin Microbiol Infect 2003; 9:980-3.
58. Nemec A, Krizova L, Maixnerova M, Musilek M. Multidrug-resistant epidemic clones among bloodstream isolates of Pseudomonas aeruginosa in the Czech Republic. Res Microbiol 2010; 161: 234-42.
59. Baquero F. From pieces to patterns: evolutionary engineering in bacterial pathogens. Nat Rev Microbiol 2004; 2:510-18.
60. Giske CG, Libisch B, Colinon C, i sur. Establishing clonal relationships between VIM-1-like metallo-beta-lactamase-producing Pseudomonas aeruginosa strains from four European countries by multilocus sequence typing. J Clin Microbiol 2006; 44:4309-15.
61. Spratt BG. Exploring the concept of clonality in bacteria. Methods Mol Biol 2004; 266:323-52.
62. Maatallah M, Cheriaa J, Backhrouf A, i sur. Population structure of Pseudomonas aeruginosa from five Mediterranean countries: evidence for frequent recombination and epidemic occurrence of CC235. PLoS One 2011; 6: e25617.
63. Pirnay JP, Bilocq F, Pot B, i sur. Pseudomonas aeruginosa population structure revisited. PLoS One 2009; 4: e7740.
64. Edalucci E, Spinelli R, Dolzani L, i sur. Acquisition of different carbapenem resistance mechanisms by an epidemic clonal lineage of Pseudomonas aeruginosa. Clin Microbiol Infect 2008; 14: 88-90.
65. Libisch B, Balogh B, Fuzi M. Identification of two multidrug-resistant Pseudomonas aeruginosa clonal lineages with a countrywide distribution in Hungary. Curr Microbiol 2009; 58: 111-6.
66. Guzvinec M, Izdebski R, Butic I, i sur. ST235, ST111 and ST132 predominate among multidrug-resistant Pseudomonas aeruginosa clinical isolates in Croatia. Rad u postupku objavljivanja.
67. Tambić A, Tambić T. Rezistencija bakterijskih izolata u 2004. g. U: Osjetljivost i rezistencija bakterija na antibiotike u Republici Hrvatskoj u 2004. g. izd. Akademija medicinskih znanosti Hrvatske, 2004.
68. Tambić A, Tambić T. Rezistencija bakterijskih izolata u 2005. g. U: Osjetljivost i rezistencija bakterija na antibiotike u Republici Hrvatskoj u 2005. g. izd. Akademija medicinskih znanosti Hrvatske, 2005.
69. Tambić A, Tambić T. Rezistencija bakterijskih izolata u 2006. g. U: Osjetljivost i rezistencija bakterija na antibiotike u Republici Hrvatskoj u 2006. g. izd. Akademija medicinskih znanosti Hrvatske, 2006.
70. Tambić A, Tambić T. Rezistencija bakterijskih izolata u 2007. g. U: Osjetljivost i rezistencija bakterija na antibiotike u Republici Hrvatskoj u 2007. g. izd. Akademija medicinskih znanosti Hrvatske, 2007.
71. Tambić A, Tambić T. Rezistencija bakterijskih izolata u 2008. g. U: Osjetljivost i rezistencija bakterija na antibiotike u Republici Hrvatskoj u 2008. g. izd. Akademija medicinskih znanosti Hrvatske, 2008.
72. Tambić A, Tambić T. Rezistencija bakterijskih izolata u 2009. g. U: Osjetljivost i rezistencija bakterija na antibiotike u Republici Hrvatskoj u 2009. g. izd. Akademija medicinskih znanosti Hrvatske, 2009.
73. Tambić A, Tambić T. Rezistencija bakterijskih izolata u 2010. g. U: Osjetljivost i rezistencija bakterija na antibiotike u Republici Hrvatskoj u 2010. g. izd. Akademija medicinskih znanosti Hrvatske, 2010.
74. Tambić A, Tambić T. Rezistencija bakterijskih izolata u 2011. g. U: Osjetljivost i rezistencija bakterija na antibiotike u Republici Hrvatskoj u 2011. g. izd. Akademija medicinskih znanosti Hrvatske, 2011.
75. Livermore DM. Discovery research: the scientific challenge of finding new antibiotics. J Antimicrob Chemother 2011; 66: 1941-4.